10-Q: HealthLynked Q2 Loss Narrows Amid Cost Cuts, Liquidity Concerns Persist

HealthLynked Corp. reported a 40% reduction in net loss for Q2 2025, driven by aggressive cost-cutting, though liquidity remains a significant concern with a going concern warning.

Summary

• Net loss for the six months ended June 30, 2025, decreased by 40% to $1,751,977, compared to $2,928,154 in the prior year.
• Loss from operations decreased by 53% to $1,052,774 for the six months ended June 30, 2025, from $2,257,527 in the same period of 2024.
• Total revenue for the six months ended June 30, 2025, decreased by 24% to $1,366,568, down from $1,799,310 in the prior year.
• Patient service revenue decreased by 23% to $1,324,855, primarily due to the discontinuation of the NWC practice and staffing changes at NCFM.
• Product revenue decreased by 56% to $25,030, attributed to decreased marketing efforts and demand.
• Subscription revenue increased by 6% to $16,683, driven by new standalone HealthLynked Network paid subscriptions.
• Cash used in operating activities significantly decreased by 50.4% to $850,089 for the six months ended June 30, 2025, compared to $1,713,549 in the prior year.
• The company continues to face substantial doubt about its ability to continue as a going concern through August 14, 2026, without additional funding.
• Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in internal controls over financial reporting.

Sentiment

Score: 3

Explanation: Despite a reduction in net loss and operating cash burn due to aggressive cost-cutting, the company faces significant challenges including declining revenue, a critically low cash balance, a worsening working capital deficit, and an explicit "going concern" warning. The heavy reliance on related-party debt and ineffective internal controls further highlight the precarious financial position.

Positives

• Net loss significantly decreased by 40% to $1,751,977 for the six months ended June 30, 2025, compared to $2,928,154 in the prior year.
• Loss from operations improved by 53% to $1,052,774 for the six months ended June 30, 2025, compared to $2,257,527 in the prior year.
• Cash used in operating activities decreased by 50.4% to $850,089 for the six months ended June 30, 2025, reflecting successful cost reduction efforts.
• Practice salaries and benefits decreased by 37% ($409,302) and other practice operating costs decreased by 36% ($310,434) for the six months ended June 30, 2025, due to focused cost reduction.
• Selling, general and administrative costs decreased by 42% ($779,742) for the six months ended June 30, 2025, due to lower overhead, stock-based compensation, and consulting costs.
• Subscription revenue increased by 6% to $16,683 for the six months ended June 30, 2025, indicating some growth in the Digital Healthcare division.
• Recognized a gain on extinguishment of debt of $174,972 for the six months ended June 30, 2025, compared to a loss of $73,567 in the three months ended June 30, 2024.

Negatives

• Total revenue decreased by 24% to $1,366,568 for the six months ended June 30, 2025, compared to $1,799,310 in the prior year.
• Patient service revenue decreased by 23% ($401,929) for the six months ended June 30, 2025, primarily due to the discontinuation of the NWC practice and changes in clinical staffing at NCFM.
• Product revenue decreased by 56% ($31,702) for the six months ended June 30, 2025, due to decreased marketing and demand.
• Cash balance as of June 30, 2025, was critically low at $20,201, a significant decrease from $76,241 at December 31, 2024.
• Working capital deficit increased to $4,566,668 as of June 30, 2025, from $3,048,832 at December 31, 2024, indicating worsening short-term liquidity.
• Accumulated deficit increased to $49,916,592 as of June 30, 2025, from $48,164,615 at December 31, 2024.
• Total liabilities increased to $6,600,768 as of June 30, 2025, from $5,352,198 at December 31, 2024.
• Total assets decreased to $1,848,450 as of June 30, 2025, from $2,222,989 at December 31, 2024.
• Amortization of original issue discounts on notes payable increased by 29% to $619,693 for the six months ended June 30, 2025, indicating higher costs associated with debt financing.
• Interest expense and other increased by 199% to $145,526 for the six months ended June 30, 2025, due to increased interest-bearing related party notes.
• Recognized a loss of $154,688 on the change in fair value of debt for the six months ended June 30, 2025, compared to a gain of $27,900 in the prior year.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern through August 14, 2026, without additional funding.
• Dependence on outside sources of capital to fund growth and operating activities.
• Uncertainty related to product development and generation of revenues and positive cash flow from the Digital Healthcare Division.
• Reliance on a single supplier for approximately 98% of product sales through the Medical Distribution Division (MOD).
• Geopolitical events (Hamas-Israel, Iran-Israel, Russia-Ukraine conflicts) could have an aggregate impact on the business, though no direct material adverse impact was noted for the current period.
• Material weaknesses in internal controls over financial reporting led to the conclusion that disclosure controls and procedures were not effective as of June 30, 2025.
• Litigation is subject to inherent uncertainties, and an adverse result could harm the business, though no material adverse effects are currently anticipated.
• Failure to complete the development of, or successfully market, the HealthLynked Network could materially adversely affect future revenue and operating profits.

Future Outlook

The company plans to profitably operate its Health Services business and continue investing in its Digital Healthcare business, specifically the HealthLynked Network. Marketing efforts for the HealthLynked Network will target large health systems, hospitals, universities, and direct-to-patient channels, leveraging MOD's medical supplies. The company intends to raise additional capital to fund its operations and growth, including through a Regulation A Offering and potentially physician telesales.

Management Comments

• "Without additional funding, the Company will not have sufficient funds to meet its obligations within one year from the date the consolidated financial statements were issued."
• "The attainment of profitable operations is dependent on future events, including obtaining adequate financing to fulfill the Company’s growth and operating activities and generating a level of revenues adequate to support the Company’s cost structure."
• "Our plan of operations is to profitably operate our Health Services business and continue to invest in our Digital Healthcare business, including our cloud-based online personal medical information and record archiving system, the HealthLynked Network."
• "We are marketing the HealthLynked Network by targeting large health systems, hospitals and universities. In addition, we are marketing via direct-to-patient marketing, affiliated marketing campaigns, co-marketing with our Medical Distribution businesses subsidiary MOD, and expanded southeast regional sales efforts."
• "We also intend to utilize physician telesales through the use of telesales representatives whom we will hire as access to capital allows."

Industry Context

The company operates in the fragmented healthcare services, digital health, and medical distribution sectors. Its strategy to consolidate physical practices and invest in a digital platform (HealthLynked Network) aligns with broader trends towards integrated care and telemedicine. However, the significant reliance on related-party debt and the going concern warning suggest challenges in securing traditional financing, potentially indicating a struggle to compete or scale effectively within these capital-intensive industries. The decline in patient service revenue and product revenue, despite cost-cutting, suggests competitive pressures or insufficient demand for its current offerings.

Comparison to Industry Standards

• The company's significant accumulated deficit of $49,916,592 and working capital deficit of $4,566,668 indicate a financial position far below industry benchmarks for healthy, growing healthcare companies.
• The reliance on related-party debt, particularly from CEO Dr. Michael Dent, for ongoing operations and extensions of existing debt, is not typical for a financially stable public company and suggests difficulty in attracting external, arm's-length financing.
• The "not effective" conclusion on disclosure controls and procedures due to material weaknesses in internal controls over financial reporting is a serious governance issue, contrasting sharply with best practices for public companies.
• The substantial doubt about the ability to continue as a going concern is a critical red flag, indicating a high level of financial distress compared to industry peers.

Corporate Governance

Legal Proceedings

• The company is not aware of any legal proceedings that will have, individually or in the aggregate, a material adverse effect on its business, financial condition, or operating results.

Related Party Transactions

• Issued 17 new convertible notes payable to a trust controlled by Dr. Michael Dent (CEO) for aggregate net cash proceeds of $710,000 during the six months ended June 30, 2025.
• Refinanced or extended five existing notes with an aggregate principal of $1,765,500 with Dr. Michael Dent's trust during the six months ended June 30, 2025.
• Maturity dates on numerous convertible notes payable to Dr. Michael Dent's trust were extended, often in exchange for warrants (e.g., June 2025 Extension, March Extension, December Extension).
• Dr. Michael Dent personally guaranteed the July 2024 Note issued by HLYK Florida LLC.
• On July 16, 2025, a trust controlled by Dr. Michael Dent advanced $40,000 to the Company in the form of an undocumented loan.
• Dr. Michael Dent's trust holds conversion rights on many convertible notes, allowing conversion into common stock at fixed or discounted market prices.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises (Regulation A offering, convertible notes conversion), significant accumulated deficit, and going concern warning pose substantial risks to investment value. Ineffective internal controls could erode confidence.
• Creditors: High reliance on related-party debt and frequent extensions of maturity dates indicate potential challenges in meeting debt obligations, increasing credit risk.
• Employees: Cost reduction efforts and "substantial downsizing" suggest job insecurity and potential impact on morale.
• Customers (Health Services): Consolidation of practices (NCFM, AEU, CCN) may impact service delivery or access, though it's framed as an efficiency measure.
• Customers (Digital Healthcare): Success of the HealthLynked Network is critical for future growth, but its development and marketing are dependent on capital.
• Suppliers (Medical Distribution): Reliance on a single supplier for 98% of product sales creates a concentration risk for the company, which could indirectly affect its ability to serve customers if supplier issues arise.

Next Steps

• Continue efforts to raise additional capital through equity or debt instruments, including the Regulation A Offering.
• Focus on marketing the HealthLynked Network to large health systems, hospitals, universities, and direct-to-patient channels.
• Leverage MOD's discounted medical supplies for HealthLynked Network members.
• Potentially hire physician telesales representatives if capital allows.
• Address material weaknesses in internal controls over financial reporting to improve disclosure controls and procedures.
• Monitor the potential IPO of PBACO Holding, LLC for the IPO Share Consideration by August 31, 2025.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a critically low cash balance ($20,201), a worsening working capital deficit ($4,566,668), and an explicit "going concern" warning. While net loss and operating cash burn improved due to aggressive cost-cutting, this came at the expense of a 24% revenue decline. The heavy reliance on related-party debt from the CEO, frequent debt extensions, and the admission of ineffective internal controls over financial reporting are major red flags. The potential for significant dilution from future capital raises and convertible debt conversions further undermines shareholder value. These factors collectively point to a highly speculative and risky investment with a high probability of further value erosion.

Keywords

healthcare, digital health, medical services, financial reporting, SEC filing, 10-Q, HealthLynked, NCFM, BTG, CCN, AEU, MOD, going concern, convertible notes, related party transactions, liquidity, cost reduction, revenue decline, net loss, financial performance